Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

What Is the Overall Sentiment on Bio-Techne Corp (TECH) Shares?

Bio-Techne Corp stock is trading -30.08% below its average target price of $69.26 after dropping -2.9% during today's morning session. Analysts are giving the Mid-Cap Biotechnology company an average rating of buy and target prices ranging from $51.0 to $90.0 per share.

The stock has an average amount of shares sold short at 5.3%, and a short ratio of 3.14. Since 1.06% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 105.6% of Bio-Techne Corp's shares being owned by this investor type.

Institutions Invested in Bio-Techne Corp

Date Reported Holder Percentage Shares Value
2025-03-31 Vanguard Group Inc 12% 18,526,824 $897,161,438
2025-03-31 Blackrock Inc. 9% 13,746,351 $665,667,036
2025-03-31 Price (T.Rowe) Associates Inc 7% 11,375,279 $550,847,876
2025-03-31 State Street Corporation 4% 6,529,887 $316,209,772
2025-03-31 Morgan Stanley 4% 5,719,540 $276,968,720
2025-03-31 Select Equity Group, Inc. 3% 5,366,003 $259,848,691
2025-03-31 Invesco Ltd. 3% 4,190,115 $202,906,315
2025-03-31 Geode Capital Management, LLC 3% 4,093,398 $198,222,795
2025-03-31 Ameriprise Financial, Inc. 2% 3,587,366 $173,718,195
2025-03-31 BAMCO Inc. 2% 3,275,806 $158,630,903

Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Bio-Techne Corp.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS